All In MedTech

FDA Clearance Tracker · P910018-S021

LIPOSORBER(R) LA-15 SYSTEM

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Oct 14, 2016 (this decision)Source: openFDAMethods & limitations

PMA supplement

The decision

FDA number
P910018-S021
Device name
LIPOSORBER(R) LA-15 SYSTEM
Applicant location
New York, NY
Received
Jul 29, 2016
Decided
Oct 14, 2016
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P910018

Device type

Device class
Class III

Every decision under product code MMY

FDA's approval statement

As written in FDA's record.

Approval for modifications to the instructions for use, operator's manual, and the patient guide for the LIPOSORBER® LA-15 System for familial hypercholesterolemia and integration of instructions for use for the LIPOSORBER® LA-15 System for familial hypercholesterolemia and focal segmental glomerulosclerosis.

Source documents

Other decisions for Kaneka Pharma America Corp.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.